C&R Research Inc. Logo

C&R Research Inc.

Leading South Korean CRO offering end-to-end clinical trial services for life science companies.

359090 | KO

Overview

Corporate Details

ISIN(s):
KR7359090008
LEI:
Country:
South Korea
Address:
서울특별시 강남구 역삼로 412 (대치동, 씨엔알빌딩), 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

C&R Research Inc. is a leading South Korean contract research organization (CRO) established in 1997. As a pioneer in the nation's clinical trial industry, the company provides comprehensive, end-to-end clinical development services for pharmaceutical, biotechnology, and medical device companies. Its expertise spans the entire trial lifecycle, including early-phase development, trial management, regulatory affairs, data management, and biostatistics. With a track record of over 1,800 domestic and global clinical trials, C&R Research positions itself as a strategic partner for navigating complex clinical pathways. The firm is actively engaged in advancing modern therapeutic areas such as digital therapeutics (DTx) and antibody-drug conjugates (ADCs), serving as a key hub for clients conducting clinical research in Asia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-04-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.1 KB
2025-03-27 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.3 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 27.7 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 26.4 KB
2025-03-19 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 175.7 KB
2025-03-11 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.2 KB
2025-03-11 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.1 KB
2025-02-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.8 KB
2025-02-12 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.5 KB

Automate Your Workflow. Get a real-time feed of all C&R Research Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for C&R Research Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for C&R Research Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.